BTX 9341
Alternative Names: BTX-9341Latest Information Update: 27 May 2026
At a glance
- Originator BioTheryX
- Class Antineoplastics; Small molecules
- Mechanism of Action Cyclin-dependent kinase 4 degraders; Cyclin-dependent kinase 6 degraders
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I HER2 negative breast cancer
Most Recent Events
- 18 May 2026 Efficacy, pharmacokinetics and adverse events data from a phase I trial in HER2-negative breast cancer released by BioTheryX
- 09 Dec 2025 Efficacy, pharmacodynamics, pharmacokinetics and adverse events data from a phase I trial in HER2-negative breast cancer presented at the 48th Annual San Antonio Breast Cancer Symposium (SABCS-2025)
- 03 Jul 2024 Phase-I clinical trials in HER2-negative breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT06515470)